secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001193125-25-281581
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei discontinues solnerstotug, starts strategic review; workforce cut 65%
----------------------------------------------------------------------------

- Discontinued solnerstotug development; Board considering sale, merger, or wind-down.
- Workforce cut ~65% to preserve cash; small team retained for strategic review.
- Cash $25.0M as of Sep 30, 2025, down from $41.3M at Dec 31, 2024.
- Q3 2025 net loss $4.6M (vs $7.3M YoY); R&D $2.5M (vs $4.6M YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/0001193125-25-281581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525281581/d844585d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-281581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer